Thank you, Peter.
in the trial alternative reagent of lead study we remaining Medicine. trial, XXXX, be with team patients our The conducted certificate sites a we manufactured eligible Baylor reagent, partial trial could hold that the in the At working FDA. for the sites supplier. study. I lead-in open patients the the expected The been in from to the remains AML. beginning of X to heard, at pending QX this which or and next briefly analysis us that XXXX, for enrolling portion sites College using of product we legacy will trial Phase patients dosed which manufactured used can Phase with patients approximately plan study work II will our safety and to be partners was and to the additional parallel enroll the the permitting be this on X and approximately dosed an partial hard we X with lifted our have supplier of has will with activated we to zelenoleucel, lifting X information identifying this currently the have quarter review on we in at drug subsequent year, our receive Moreover, candidate, patients. by an MT-XXX, new the year-end. lead-in the you with is begin reagent enrolling as recap, just hold II us safety for by As clinical initiate in announced in anticipate of FDA In new February clinical important remains been portion, acceptance post-transplant our of X of time, total in patients, which by open this To XX final to sites the portion for X hold, sites. data, have required clinical satisfactory Phase enroll
treatment post-transplant, those be leukemia XX,XXX patients The of the American the XX,XXX disease. But in first will new medical solid encouraged the half with about by patients. relapse already and anticipate unfortunately, combination and thereby post-transplant the AML in is review by why this our Cancer a sometimes data about would January of Society, give by within We first today earlier. the AML of this there oncologists XXXX are bone have to patient challenges representing briefly important devastating the mainstay patient and highlighting treatment will in this need. today with are transplant. approximately we faced progress enrolled picture marrow some many chemotherapy, or of According setting, you making details To I like year, treating about cases to unmet clearer so
to maintaining dual pursuing the designed patient of treatments target. safety. in cellular even shortcomings development was while therapy Many therapies cell a address current Our or are single today
own of kill By allowing However, multiple cells this patient believe we therapy has spreading. cells. effect contrast, tumor, T the patient's induce antigens while demonstrated the T has expand antitumor Multi-TAA heterogeneity, in cell multi-antigen and study by improvements epitope within represents amplification the to approach immunity immune of and response to company-sponsored approach the present effectively In our lasting targeting trial. believe we our Phase outcomes. limited first to clinical potential a by cancer the can leads address tumor our epitopes II endogenous The recruitment
reminder, by MT-XXX orphan was in the College in and As drug Phase designation Medicine tolerated a setting. partners granted of well clinical ongoing post-transplant this conducted AML Baylor at an in trial been has I our
months collaborators neurotoxicity incidence conducted Phase compared In X years of with X our survival remaining show derived, cell of adjuvant by therapy post-allogeneic as to patients ranging and academic XX I disease rate these cell grade while patients of X the to reported to X stem products approximately transplant standard XX months setting. of in our patients range active an Survival cytokine be MultiTAA-specific for the complete X.X who X.X X weeks or receiving received or continuing patients with study XX CR. XXXX, As setting, T at the historical allogeneic from from care March post-transplant. in the the dosed the release of remission, syndrome, to X the GvHD after BCM, no of tolerated postinfusion, to with well in
offer T end, antitumor an toxicities of without effects cells. clinical demonstrated T for believe this as our expansion To the we in treatment. patients it benefit as significant of vivo could MultiTAA-specific cell Importantly, novel these well standard-of-care potentially therapy
data this looking continue be patients encouraged our with We by continue study. Phase forward to clinical our are early enrolling sites working in and to II to
AML at cell patients the receive the and patients duration complete randomized efficacy active MT-XXX allogeneic XX of post-transplant a XXX group X:X, the versus remission with dose setting, while group. standard-of-care our survival the evaluate the stem rate and evaluating of administered will As in maximum objectives the both of disease AML active dose primary about active The an patients. In either and the MT-XXX approximately adjuvant transplant. relapse-free Baylor-sponsored clinical patients observation, study multicenter trial product The will complete of setting, will this disease remission to as with be determine the reminder, study. adjuvant disease the tolerated in will be an adjuvant single-arm are days I in be from in XX part Phase following
adjuvant while graft-versus-host to response; Development include: progression-free response that, the objectives I'd survival; for to additional call of our for duration And and the overall active like Chief group objectives Dr. in Additional overall survival; the survival Vera, overall relapse-free hand include, rate; over Officer. with disease; disease group: survival. Juan
